DprE1 Inhibitors
Learn MoreGLUT1 inhibitors are a class of pharmaceutical compounds that target the GLUT1 transporter protein which plays a key role in glucose uptake in cells By inhibiting GLUT1 these inhibitors can effectively limit glucose uptake and metabolism in specific tissues or cell types This targeted inhibition has significant potential in the treatment of various diseases including cancer where high glucose utilization is a hallmark By suppressing glucose uptake through GLUT1 inhibition these inhibitors have the potential to impair tumor growth and increase the efficacy of other cancer therapies Our company offers a range of high-quality GLUT1 inhibitors for biomedical research and therapeutic applications
Catalog Number | Chemical Name | CAS # | Price |
---|---|---|---|
BC-0150 | Resveratrol | 501-36-0 | Online Inquiry |
BC-0616 | Naringenin | 480-41-1 | Online Inquiry |
EI-0348 | BAY-876 | 1799753-84-6 | Online Inquiry |
EI-0969 | Fasentin | 392721-37-8 | Online Inquiry |
EI-1929 | Rubusoside | 64849-39-4 | Online Inquiry |
EI-2065 | STF-31 | 724741-75-7 | Online Inquiry |
EI-2315 | WZB117 | 1223397-11-2 | Online Inquiry |
GLUT1 inhibitors offer valuable applications in medical research and potential therapeutic interventions Researchers can utilize these inhibitors to study the role of glucose transporters in various cellular processes such as energy metabolism and cancer cell proliferation By inhibiting GLUT1 scientists can better understand the impact of glucose availability on cellular functions and potentially develop new strategies for targeting cancer cells that heavily rely on glucose
In the field of drug development GLUT1 inhibitors show promise as potential anticancer agents Cancer cells often exhibit an increased reliance on glucose for their rapid growth and proliferation By targeting GLUT1 these inhibitors can disrupt the glucose uptake by cancer cells potentially inhibiting their growth and survival This application holds great hope for the development of more effective and targeted therapies in the fight against cancer
Furthermore GLUT1 inhibitors offer important applications in metabolic disorders particularly in the management of Type 2 diabetes By inhibiting glucose transporters these inhibitors can reduce the uptake of glucose into cells helping to regulate blood sugar levels This can contribute to better control of diabetes symptoms and potentially reduce the risk of complications associated with the condition
In summary GLUT1 inhibitors hold immense potential for research advancements and therapeutic interventions in understanding and addressing various diseases including cancer and metabolic disorders Their ability to target glucose transporters opens up new avenues for exploring cellular processes and developing innovative treatment strategies
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.